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INFECTION (including HIV, CAP)
INFECTIONS (including HIV, CAP)—Clinical Outcomes
Studies
PIN1
CLINICAL PRACTICE GUIDELINE EVALUATION: NEONATAL
INFECTION WITH MATERNAL HISTORY OF PREMATURE
RUPTURE OF MEMBRANE (PROM)
Srijariya W1, Ratanakorn W2, Chamnanwanakij S2, Saeng-arun P2
1Mahidol University, Bangkok,Thailand; 2Phramongkutklao Hospital and
College of Medicine, Bangkok,Thailand
OBJECTIVES: To evaluate Phramongkutklao CPG for treatment
of neonatal infection in newborn infants with maternal history
of PROM for ≥18 hours and the impact on saving hospital cost.
METHODS: Prospective cohort study. Infants with maternal
history of PROM were categorized into 1 of 3 groups: group I,
having symptoms within 6 hours after birth; group II, having
history of maternal chorioamnionitis and group III, healthy
infants without history of maternal chorioamnionitis. All infants
in group I and II were treated with antibiotics. Infants in group
III were ranked by using PROM scoring system. The success of
CPG was deﬁned as no re-admission due to infection occurred
within 28 days of age. Logistic regression was used to determine
the association between neonatal infection and risk factors.
RESULTS: In total, 109 of 5182 (2.10%) infants born during
study period had maternal history of PROM, 5 cases were
excluded. Twenty-nine of 104 (27.88%) infants had infection
and were treated with antibiotics. The CPG successfully identi-
ﬁed different risk of infection in 102 of 104 (98.08%) infants.
The use of CPG reduced a number of infants treated with 
antibiotics from 81 to 38 (53.09%) compared to the previous
strategies. The relative risk of 1-minute Apgar scores £5, 
duration of PROM >72 hours, gestational age <34wk, 
birth weight 1500–2500g and birth weight <1500g were 3.82
(95%CI 2.43–5.99), 3.47 (95%CI 1.56–7.72), 5.33 (95%CI
2.77–10.25), 3.40 (95%CI 1.84–6.28) and 6.17 (95%CI
3.67–10.35), respectively. Logistic regression analysis equation
was log [Infection Rate] = 4.148 - 3.028 [gestational age <34
wk] -2.444 [gestation age 34–37wk] -3.029 [1-minute Apgar
score] (R2 = 0.84). Using CPG reduced expenditure for treatment
from 469,395 Baht to 237,700 Baht or 139,017 Baht per year.
CONCLUSIONS: Phramongkutklao CPG on PROM is safe and
cost saving for managing newborn infants at risk.
INFECTION (including HIV, CAP)
INFECTIONS (including HIV, CAP)—Cost Studies
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COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN
IN SUSPECTED METHICILLIN–RESISTANT
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Hardewig J4, Duttagupta S5
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OBJECTIVES: Linezolid, a novel antibiotic, has demonstrated
efﬁcacy in known or suspected methicillin-resistant Staphylo-
coccus aureus (MRSA) infections. Among patients with MRSA
nosocomial pneumonia, survival and clinical cure rates (resolu-
tion of baseline signs and symptoms) were better for those
treated with linezolid versus vancomycin: 80% versus 63.5%
(survival) and 59% versus 35.5% (clinical cure) (Chest.
2003;124:1789–97). We evaluated the economic impact of these
clinical outcomes from the German perspective. METHODS: A
decision-analytic model was developed to examine the costs and
outcomes of using linezolid versus vancomycin in hospitalized
patients with nosocomial pneumonia in a German setting. Five
German physicians experienced in treating nosocomial pneumo-
nia provided resource utilization data through structured inter-
views. Costs from published sources (Rote Liste, EBM,
DKG-NT) were applied to tests, adverse events, isolation and
days of intravenous and oral (linezolid only) treatment and hos-
pitalization by ward type (medical, intensive-care). The model
assumed 50% of suspected MRSA patients had proven MRSA.
Outcomes included total costs per patient, cost per death
avoided, cost per life-year gained and cost per cure. RESULTS:
An additional 11% of patients treated with linezolid (71%)
versus vancomycin (60%) were cured. Average total cost per
episode was 12,288€ versus 11,444€ for linezolid-versus van-
comycin-treated patients, translating to €7756 per additional
patient cured. Death rates were 21% (linezolid) versus 34%
(vancomycin), resulting in an average 2.3 life-years gained per
linezolid patient in a 65-year-old cohort (13.6 versus 11.3 years).
Using incremental costs from the treatment episode, the costs per
life-year gained and death avoided were 371€ and 5124€, respec-
tively. Although the model was sensitive to the percentage of
proven MRSA cases and costs accrued by patients who die,
varying these parameters by 25% did not change the overall con-
clusions. CONCLUSIONS: Linezolid is cost-effective versus 
vancomycin in the treatment of nosocomial pneumonia due 
to suspected MRSA.
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OBJECTIVES: A recent multi-country clinical trial of compli-
cated skin and soft-tissue infections (cSSTI) due to proven or sus-
pected methicillin-resistant Staphylococcus aureus (MRSA)
demonstrated superior efﬁcacy with linezolid compared with
vancomycin. In this study, we estimated whether treatment with
linezolid was also cost-effective versus vancomycin in patients
with cSSTI. METHODS: All 1180 patients from the clinical trial
(592 linezolid, 588 vancomycin) admitted to hospitals in 16
countries with cSSTI due to suspected or proven MRSA were
studied. Costs of hospitalization for each patient were estimated
by applying country-speciﬁc 2003 per diem hospital costs for
days in the medical/surgical, intensive care, or the step-down
units. Costs of intravenous (IV) therapy were applied to the dura-
tion of IV treatment plus administration costs. Medications were
valued at wholesale acquisition cost. Medical resource costs from
available countries were used before converting to US dollars
using purchasing power parity adjustments. Furthermore, both
costs and outcomes were risk adjusted using multivariate
methods to account for patient population differences between
countries. The cost effectiveness was measured as incremental
cost per additional patient cured. RESULTS: There were no sig-
niﬁcant differences at baseline in clinical and demographic char-
acteristics between the linezolid and vancomycin groups.
Average risk-adjusted cost for patients treated with linezolid was
$3629 versus $4140 (P < 0.0001) for patients treated with van-
comycin. In addition, the predicted cure rate for the linezolid
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group was 92% compared with 88% for the vancomycin group
(P < 0.0001). The lower costs for patients treated with linezolid
were attributable to the switch to oral therapy and earlier hos-
pital discharge. CONCLUSIONS: A higher cure rate in combi-
nation with lower overall treatment costs distinguishes linezolid
as a dominant therapy option compared with vancomycin in
patients with proven or suspected MRSA cSSTI.
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COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS
VANCOMYCIN IN THE TREATMENT OF VENTILATOR-
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OBJECTIVES: To asses the cost-effectiveness of linezolid (600
mg IV, every 12h for 10 days), compared with vancomycin (1g
IV, every 12h for 10 days) for the treatment of ventilator-asso-
ciated pneumonia (VAP). METHODS: A decision model analy-
sis was performed from the National Health System perspective.
The primary outcome was the incremental cost-effectiveness of
linezolid in terms of cost per added QALY gained. The secondary
outcome was the marginal cost per year of life saved (YLS) gen-
erated by using linezolid. Clinical cure and survival rates 
estimates were derived from a retrospective analysis of two ran-
domized, double-blind trials comparing linezolid with van-
comycin. QALY were based on time-trade off study. Four subsets
of VAP patients were considered: all, with Gram-positive (GP),
with S. aureus (SA) and with methicillin-resistant SA (MRSA)
infection. Resources use and unit costs (2003€) were obtained
from Spanish VAP treatment guidelines and Spanish health costs
databases. Costs were evaluated for the acquisition of antibiotic
treatments, adverse reactions treatment, and antibiotic rescue,
extra diagnostic tests, the intensive care unit stay and medical
visits due to therapeutic failure. RESULTS: The additional QALY
and YLS per linezolid-treated patients were 0.392, 0.688, 0.606,
1.805 and 0.471, 0.829, 0.729, 2.175, respectively, compared
with that of vancomycin (all, GP, SA and MRSA VAP, respec-
tively). The additional cost per QALY gained obtained with 
linezolid was 1803.87€, 997.25€, 1149.00€ and 348.85€, respec-
tively. The additional cost per YLS obtained with linezolid was
1501.31€, 827.63€, 955.13€ and 289.51€, respectively. These
values are well below the acceptable threshold in Spain of
30,000€ per QALY/YLS gained. The sensitivity analyses con-
ﬁrmed the robustness of the base case analysis. CONCLU-
SIONS: According to this model, linezolid is a cost-effective
alternative to vancomycin for VAP patients in Spain, with an
additional cost per QALY/YLS gained below the acceptable
threshold for new therapies.
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MEASURING RESOURCE USE AND DIRECT COSTS IN
PATIENTS WITH HEPATITIS C VIRUS MANAGED IN A
GASTROENTEROLOGY AND HEPATOLOGY SERVICE
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13D Health Research, Barcelona, Barcelona, Spain; 2University Hospital
of Bellvitge; 33D Health Research
OBJECTIVES: Hepatitis C (HCV) is a serious health problem
affecting around 170 million people worldwide. A considerable
health care burden is expected over the short to medium term,
because of earlier peaks in incidence rates and the presence of
undetected cases. The aim of the present study was to measure
resource use and direct costs associated with the management of
hepatitis C patients in a hospital-based Gastroenterology and
Hepatology Service (GAS). METHODS: A model of patient ﬂow
through the department was constructed, and expert opinion
was used to deﬁne relevant clinical sub-groups. Hospitalizations,
outpatient care and diagnostic tests for the group as a whole and
for each clinical sub-categoriy were calculated for the 4 month
study period using information from hospital records, depart-
ment protocols, and expert opinion. Unit costs were obtained
from the hospital administrative database. Antiviral treatments
were not included as they are not ﬁnanced from the GAS budget.
RESULTS: Data on use of resources and costs were obtained for
a total of 584 patients. The total cost of treating HCV patients
in the GAS for the study period was 600,343€ (1028€ per
patient). A total of 52% of these costs were attributable to diag-
nostic tests, 45% to hospitalization, and 3% to outpatient visits
two. The most costly clinical categories in overall terms were
post-transplant patients and chronic hepatitis patients, with total
costs for the 4-month study period of 136,185€ and 116,502€,
respectively. The two clinical categories with the highest per-
patient costs were pre-transplant decompensated cirrhosis and
hepatocarcinoma in decompensated cirrhosis, with per-patient
costs for the study period of 4731€ and 4498€, respectively. Hos-
pitalization was the principal cost driver in both instances. CON-
CLUSIONS: The study is useful in providing resource use and
cost information by clinical sub-categories which will help esti-
mate future resource use needs for these patients.
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OBJECTIVES: To evaluate lifetime clinical effectiveness and
cost-effectiveness of different antiviral treatment (AVT) strategies
in patients with chronic hepatitis C (CHC) using recent German
guidelines, that recommend basing drug dosage, intended treat-
ment duration and early stopping rules on the genotype of the
hepatitis C virus (HCV). METHODS: The German Hepatitis C
Model (GEHMO), a validated Markov model, was used to
project clinical events, life expectancy, QALYs, and lifetime costs
for the following AVT strategies: 1) no AVT (NoAVT); 2) Inter-
feron alfa-2b plus ribavirin for 48 weeks (IFN); 3) Peginterferon
alfa-2b plus ribavirin for 48 weeks (PEG); and 4) Peginterferon
alfa-2b plus ribavirin according to the German guidelines with
genotype-dependent AVT duration, dosing and early stoppage in
HCV-positive patients after 12 weeks (GUIDE). Incremental
cost-effectiveness ratios (ICER) were calculated from a societal
perspective. Clinical and drug utilization data were derived from
a clinical trial and from a survey of German hepatologists.
RESULTS: Combination therapy with peginterferon alfa-2b and
ribavirin (PEG or GUIDE) reduced the 20-year risk for decom-
pensated cirrhosis, hepatocellular carcinoma, liver transplanta-
tion, and liver-related death by more than 50%, compared to no
antiviral treatment. PEG increased life expectancy by 5.0 life
years and GUIDE increased life expectancy by 4.9 years com-
pared to NoAVT. GUIDE dominated IFN, so compared to
NoAVT, discounted ICERs were 1500€/QALY for GUIDE and
